

2011-2012

Support from Pharmaceutical Companies and Device Manufacturers and American Heart Association Total Corporate Support

We value the trust placed in us by our donors, supporters and the general public, and we feel the best way to continue to earn that trust is to make the association's finances as transparent as possible. In fact, the American Heart Association has consistently met the high standards of the [Better Business Bureau's Wise Giving Alliance \(WGA\)](#), the premier organization evaluating charitable organizations.


Most of the revenue recorded by the American Heart Association comes from sources other than corporations. These sources include contributions from individuals, foundations and estates as well as investment earnings and revenue from the sale of educational materials. Contributions from corporations account for just 24.9 percent.

Financial support from corporations helps the association's programs and campaigns more effectively achieve our goals of improving the cardiovascular health of all Americans and saving more lives. All corporate relationships are required to comply with the association's corporate relations policies, and regional and national corporate relationships are approved by a committee of national volunteers and executive staff.

Total corporate support is comprised of unrestricted gifts and special event and program sponsorships, and includes support committed to the entire American Heart Association, including National Center, its Affiliates and local offices. It represents approximately 24.9 percent of the AHA's \$639,525,149 in total revenue (2011-2012 audited financial statements).

Support that the American Heart Association receives from pharmaceutical companies, device manufacturers and health insurance providers is included within total corporate support and represents approximately 2.4 percent of the association's total revenue (2011-2012 audited financial statements). The majority of funding from these sources occurs at the national level.

The revenue figures below include the total amount of funds committed during fiscal year 2011-2012, noting that, in some cases, the funds will be paid out in future years.



NOTE: The Pie Chart above shows income committed in fiscal year 2011-2012 to the American Heart Association from pharmaceutical companies, device manufacturers and health insurance providers and the amount of total corporate support committed to AHA association-wide, compared to all sources of revenue.

Listed below in the middle column is cash received by the American Heart Association from pharmaceutical companies, device manufacturers and health insurance providers during fiscal year 2011-2012.

In addition, in the right column, we have listed revenue that was committed to the American Heart Association during fiscal year 2011-2012, but will actually be received in future years. An example is a multi-year sponsorship of an American Heart Association program or campaign.

FY 2011-2012 Contributed income and advertising revenue contributed to AHA¹ from pharmaceutical, medical device companies and health insurance providers		
Corporation	Total Cash Received During FY 2011-2012 on Prior and Current Year Commitments²	Current Year FY 2012-2012 Commitments Receivable in the Future
Abbott Vascular	37,500	-
Accumetrics	32,500	-
Aetna	125,000	105,000
Allergan, Inc	295,000	-
Amgen	105,000	-
Amarin	25,000	300,000
Amylin/Lilly	30,000	-
Anthem Blue Cross Blue Shield	265,000	160,000
Arthrex	85,000	-
Astellas	99,725	-
AstraZeneca	319,250	215,000
Asubio	2,473	-
Bayer	6,512	150,000
Blue Cross Blue Shield	110,000	-
Boehringer Ingelheim Pharmaceuticals	302,363	3,050,000
Boston Scientific	145,000	-
Bristol-Myers Squibb Company	20,000	-
Bristol-Myers Squibb/Pfizer	344,500	-
Bristol-Myers Squibb/Sanofi Joint Venture	100,000	-
Capricor	2,000	-
Chugai	2,473	-
Cigna	25,000	430,000
Codman	20,000	-
Covidien	50,000	-
Covidien/ev3 Neurovascular	100,000	-
Daiichi Sankyo	37,363	-
Eisai	2,473	-
Eli Lilly	50,000	-
Forest Laboratories	160,000	-
GE Healthcare	30,000	-

Genentech	472,500	55,000
Gilead	30,000	30,000
GlaxoSmithKline	50,000	-
Great West Life	150,000	-
Harvard Pilgrim Healthcare	140,000	-
Horizon Blue Cross Blue Shield of NJ	35,000	-
Isis Pharmaceuticals	2,500	-
Janssen	-	468,000
Johnson & Johnson/Listerine	-	350,000
Kaiser Permanente	162,500	-
LipoScience	-	50,000
MDCO	30,000	-
Medtronic, Inc	227,500	130,000
Merck	2,261,931	475,000
Merck (Coricidin)	1,085,000	-
Merck/Schering-Plough	308,363	-
Norvartis Pharmaceuticals	167,348	-
Norvartis KK	6,237	-
Nono Nordisk	57,500	-
Omron Healthcare, Inc	250,000	-
Ortho McNeil/Janssen	2,079,000	-
Pfizer	110,000	-
Philips	80,000	350,000
Physio-Control	20,000	-
Premera Blue Cross	50,000	50,000
PRI Healthcare/Janssen	-	50,000
Regence Blueshield of Idaho	40,000	60,000
Sanofi	183,750	-
Sanofi-Aventis	-	50,000
Schreing Corporation	20,000	-
Schering-Plough	187,500	-
Shionogi	6,181	-
Southeastern Emergency Equipment	50,000	-
Takeda	109,725	-
United Healthcare	755,000	-
WellPoint	4,500,000	-
Zoll Medical	25,000	-
Totals	\$16,581,667	6,528,000

Note: (1) Reflects all corporate contributions to National Center and 10 highest corporate contributions to each Affiliate.

Note (2) Column includes cash received on commitments from contracts and conferences. This was recorded as revenue in FY 2008-2009, FY 2009-2010, FY 2010-2011 and FY 2011-12.